For U.S. Healthcare
Professionals Only

Resources and Support

Sanofi Genzyme is committed to helping your patients navigate each stage of their treatment journey. We offer a range of support services from copay assistance to personalized patient support to address your patients’ unique needs.

Support For Your Patients

About CareConnectPSS®

CareConnectPSS, personalized support services for patients, represents Sanofi Genzyme’s more than 25-year commitment to supporting the rare disease community. CareConnectPSS is designed to support each patient’s unique journey.

CareConnectPSS support includes:

  • Dedicated CareConnectPSS Case Managers and Patient Education Liaisons
  • Disease-specific information and resources
  • Genetic education and information on testing and diagnostics
  • Care coordination for treatment
  • Help with handling insurance issues
Contact a case manager

1-800-745-4447, Option 3

Connect with us online: www.CareConnectPSS.com

Copay assistance program

Copay Assistance Program

The Sanofi Genzyme Copay Assistance Program helps eligible individuals in the United States who are prescribed Fabrazyme pay for their qualifying out-of-pocket drug and infusion-related (mixing and administration of the drug as well as infusion supplies such as saline, IV tubing, etc.) expenses, including copays, coinsurance, and deductibles.


Learn more about the Sanofi Genzyme Copay Assistance Program.

Billing and reimbursement

Billing and reimbursement for Fabrazyme

Treatment with Fabrazyme is a covered benefit under most major insurance plans, as well as Medicare and Medicaid programs. Sanofi Genzyme is committed to working with providers, as well as public and private payers, to help ensure access to treatment for patients who would medically benefit from Fabrazyme.

About billing and reimbursement for Fabrazyme

Fabry Registry

The Fabry Registry: Committed to increasing the understanding of Fabry disease and improving the lives of those living with this rare condition

The Fabry Registry, sponsored and administered by Sanofi Genzyme, is the largest international patient registry database dedicated to Fabry disease. It is led by a group of physicians with extensive experience in managing patients with Fabry disease.

The Fabry Registry has been established in order to better understand the variability and progression of Fabry disease in the population as a whole and in women specifically, and to monitor and evaluate long-term treatment effects of Fabrazyme.

The Registry also monitors the effect of Fabrazyme on pregnant women and their offspring. Pregnant women and women of childbearing potential should be encouraged to enroll in the Fabry patient registry. Participation is voluntary and may involve long-term follow-up.

The Registry’s database helps increase the understanding of Fabry disease by:
  • Providing individualized patient reports and informative clinical summaries
  • Encouraging physician collaboration and shared expertise
  • Facilitating important publications

In addition, physicians may publish their own data or publish analyses on aggregate Registry data.


To register or find out more, please visit www.registryNXT.com

References:
  1. Fabrazyme prescribing Information. Cambridge, MA. Genzyme Corporation.